NCT Number: NCT06172478
Phase: PHASE2
Trial Summary: This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/a – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Daiichi Sankyo
Acronym:
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives